NDA 019952 · B Braun
Heparin Sodium 25,000 Units In Dextrose 5% In Plastic Container
Heparin Sodium · Injection
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
Jul 20, 1992
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,126
334 Phase 3, 112 recruiting
FAERS reports
723
648 serious, 145 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 26, 2026.
Heparin Sodium in 5% Dextrose Injection is indicated for: Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation) Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arterial embolism Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. Heparin sodium is indicated for: ( 1 ) Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation; Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism; Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.
Mechanism: Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not lyse...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 20, 1992 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
- HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER · HEPARIN SODIUM 5,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER · HEPARIN SODIUM 10,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER · HEPARIN SODIUM 4,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Heparin" as an intervention, any sponsor and status, largest first.
- Study of Low Molecular Weight HeparinsPivotal-lookingStatus unknown
Herlev HospitalAcademic, hospital or other
NCT06020560 · 65,000 participants (planned) · Start Mar 23, 2023 · Primary completion Mar 23, 2025
Drug: Dalteparin Prefilled Syringe; Tinzaparin profiled syringe · For: Anticoagulant; Venous Thromboembolism; Prophylaxis and 1 more
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 9 sites in all
- Delivery and Implementation of a Randomised Crossover Trial on ThrombosisPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06937372 · 21,194 participants (planned) · Start Jul 1, 2026 · Primary completion Oct 31, 2027
Drug: Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.; Low molecular weight heparin (LMWH) · For: Hip Fractures; Venous Thromboembolism (VTE)
Sites: London, United Kingdom
- Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00077792 · 20,506 participants · Start Oct 2002 · Primary completion Dec 2006
Drug: Enoxaparin sodium (XRP4563) · For: Myocardial Infarction; Acute ST-Segment Elevation
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 48 sites in all
- Michelangelo - Oasis 5Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00139815 · 20,078 participants · Start Apr 2003 · Primary completion Dec 2005
Drug: Fondaparinux; enoxaparin · For: Thromboembolism
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Higher vs. Lower Dose Heparin for PCIPivotal-lookingRecruiting
Population Health Research InstituteAcademic, hospital or other
NCT04049591 · 16,000 participants (planned) · Start Mar 2, 2022 · Primary completion Oct 8, 2024
Drug: Higher Dose UFH; Lower Dose UFH · For: Cardiovascular Diseases; Percutaneous Coronary Intervention
Sites: Hamilton, Canada
- Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00093158 · 13,800 participants · Start Aug 2003
Drug: Angiomax (bivalirudin) anticoagulant · For: Unstable Angina; Myocardial Infarction; Acute Disease
Sites: New York, New York
- Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive StrategyPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01076764 · 13,220 participants · Start Apr 2010 · Primary completion May 2013
Drug: Otamixaban; Placebo (for Otamixaban) and 4 more · For: Acute Coronary Syndrome
Sites: Huntsville, Alabama; Phoenix, Arizona; Anaheim, California · 607 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective319
- general physical health deterioration86
- hyponatraemia85
- stress85
- multiple organ dysfunction syndrome84
- sepsis84
- abdominal pain79
- ascites78
- ventricular fibrillation78
- abdominal distension77
- appendicitis77
- appendicolith77
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2012 | 6 |
| 2013 | 2 |
| 2015 | 3 |
| 2016 | 22 |
| 2017 | 23 |
| 2018 | 45 |
| 2019 | 32 |
| 2020 | 29 |
| 2021 | 62 |
| 2022 | 54 |
| 2023 | 163 |
| 2024 | 202 |
| 2025 | 47 |
| 2026 | 32 |
Recalls
3 FDA enforcement reports for this application.
May 9, 2023 · Class II · Terminated
Subpotent: Low anti-factor IIa Potency.
Mar 1, 2023 · Class II · Terminated
Subpotent Drug: low Anti-Factor IIa potency.
Jun 13, 2019 · Class II · Terminated
Subpotent Drug: low out-of-specification results were identified for the drug anti-factor IIa potency which is intended to ensure that the potency of heparin is within the USP specifications.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Thrombolytic therapy for pulmonary embolism.
Zuo Z, Yue J, Dong BR, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Anticoagulation for people receiving long-term haemodialysis.
Natale P, Palmer SC, Ruospo M, et al. · Cochrane Database Syst Rev 2024 · Meta-Analysis, Systematic Review
- Taurolidine/Heparin Lock Solution and Catheter-Related Bloodstream Infection in Hemodialysis: A Randomized, Double-Blind, Active-Control, Phase 3 Study.
Agarwal AK, Roy-Chaudhury P, Mounts P, et al. · Clin J Am Soc Nephrol 2023 · Randomized Controlled Trial, Multicenter Study
- Low-molecular-weight heparin in the prevention of unexplained recurrent miscarriage: a systematic review and meta-analysis.
Scarrone M, Salmeri N, Buzzaccarini G, et al. · Sci Rep 2024 · Meta-Analysis, Systematic Review
- Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.
López-Briz E, Ruiz Garcia V, Cabello JB, et al. · Cochrane Database Syst Rev 2022 · Meta-Analysis, Systematic Review
- Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation.
Hasegawa D, Sato R, Prasitlumkum N, et al. · ASAIO J 2023 · Systematic Review, Meta-Analysis
Sponsor: B Braun · Also marketed as Heparin Sodium 20,000 Units In Dextrose 5% In Plastic Container
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.